Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HRMY stock price vs QCOM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QCOM's multiple
Needs QCOM P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · QCOM FY 2025 (ended Sep 28, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
QUALCOMM INC/DE · implied price per share
Bear
$95.67
Base
$112.55
Bull
$129.43
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.76x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
0.40x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$10.16B
Total debt
Interest-bearing obligations outstanding
$163.66M
$16.18B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
Broadcom Inc.
HRMY vs AVGO
INTEL CORP
HRMY vs INTC
NVIDIA CORP
HRMY vs NVDA
TEXAS INSTRUMENTS INC
HRMY vs TXN
ADVANCED MICRO DEVICES INC
HRMY vs AMD
Qorvo, Inc.
HRMY vs QRVO
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY can sustain its 21.5% revenue growth and high ROIC without a major margin reset, then HRMY looks attractive to own or add because its current price is far below QCOM-implied $95.34 and still supported by historical and DCF ranges.
HRMY trades at $37.26 versus a QCOM-implied price of $95.34, implying 155.9% upside and a large valuation discount on both earnings and sales multiples. The gap is notable because HRMY also has a lower P/E, P/S, EV/EBITDA, and EV/Revenue than QCOM, suggesting the market is pricing in a much less demanding growth and quality profile.
Supporting Metrics
